1. Home
  2. SOBR vs DRMA Comparison

SOBR vs DRMA Comparison

Compare SOBR & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOBR Safe Inc.

SOBR

SOBR Safe Inc.

HOLD

Current Price

$1.41

Market Cap

2.4M

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$2.17

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOBR
DRMA
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SOBR
DRMA
Price
$1.41
$2.17
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
70.8K
107.6K
Earning Date
11-12-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$364,164.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
98.07
N/A
52 Week Low
$1.27
$2.21
52 Week High
$22.00
$23.70

Technical Indicators

Market Signals
Indicator
SOBR
DRMA
Relative Strength Index (RSI) 31.21 29.93
Support Level $1.40 $2.21
Resistance Level $2.17 $2.98
Average True Range (ATR) 0.16 0.26
MACD 0.02 -0.03
Stochastic Oscillator 1.26 2.91

Price Performance

Historical Comparison
SOBR
DRMA

About SOBR SOBR Safe Inc.

Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Share on Social Networks: